Regeneron's Dupixent leads growth as Eylea sales decline and valuation is attractive, but growth is delayed by 2-3 years.

Sanofi and Regeneron's Dupixent (dupilumab) has been approved by the FDA for the treatment of chronic spontaneous urticaria (CSU), a condition that causes painful hives that often don't respond to ...

Learn how Dupixent helps diverse eczema patients and why inclusive clinical trials are vital for fair healthcare.

There's a lot of exciting therapies that have emerged over the last 10 years and there's more therapies coming down the ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Regeneron Pharmaceuticals. If we consider the specifics of each trade, it is accurate to state that 50% of the investors ...

Recent FDA decisions added new options for dermatologists involved in treating patients with psoriasis, bullous pemphigoid ...

Kymera signs $750 million CDK2 drug deal with Gilead and earns $20 million from Sanofi as KT-485 advances toward clinical trials in inflammatory diseases.

Nektar Therapeutics (NASDAQ: NKTR) stock exploded nearly 157% following news that Rezpeg, the company’s experimental ...

Despite Nektar’s share price shooting up as much as 175% on Tuesday, William Blair maintained that “there is an absence of ...

Sanofi and Regeneron estimate that there are around 220,000 COP patients in the EU who could be eligible for treatment with Dupixent, representing a massive new opportunity for a drug that is ...

Eli Lilly’s tirzepatide is expected to be worth $62 billion annually by 2030, according to Evaluate. That valuation would be ...

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.